CP-339818 is a potent and selective negative allosteric modulator of the metabotropic glutamate receptor 1 (mGlu1), primarily utilized in medicinal chemistry and pharmacology research due to its therapeutic potential. It targets mGlu1 receptors involved in glutamate signaling, which plays a key role in various physiological processes. Researchers have explored its applications in treating neurological disorders, including anxiety, depression, chronic pain, Parkinson's disease, and Alzheimer's disease, where it helps regulate neurotransmitter activity, reduce neuroinflammation, and mitigate symptoms. Additionally, mGlu1's role in certain cancers, such as melanoma, has led to studies on its anti-cancer properties by inhibiting tumor cell growth. Its pharmacological profile also supports use in cardiovascular research for understanding heart-related conditions. The compound's selectivity and efficacy make it a valuable tool in drug development and preclinical studies for discovering new treatments for complex diseases.